Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CCR2 | P41597 | 3/20 | 0.53 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4227463 | 1.00 | DGAT1 (0.60) | DGAT1KDM4EMEN1NPC1MAPT | |
| SCHEMBL4227457 | 1.00 | DGAT1 (0.60) | DGAT1KDM4EMEN1NPC1MAPT | |
| SCHEMBL4226838 | 0.87 | DGAT1 (0.64) | DGAT1RAB9A | |
| SCHEMBL4226842 | 0.87 | DGAT1 (0.64) | DGAT1RAB9A | |
| SCHEMBL4226844 | 0.87 | DGAT1 (0.64) | DGAT1RAB9A | |
| SCHEMBL4233152 | 0.81 | DGAT1 (0.63) | DGAT1NPC1RAB9AKMT2A | |
| SCHEMBL4233157 | 0.81 | DGAT1 (0.63) | DGAT1NPC1RAB9AKMT2A | |
| SCHEMBL4233151 | 0.81 | DGAT1 (0.63) | DGAT1NPC1RAB9AKMT2A | |
| SCHEMBL13752788 | 0.81 | DGAT1 (0.69) | DGAT1RAB9A | |
| SCHEMBL4221543 | 0.79 | DGAT1 (0.60) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215780-A1 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-27 | — | — | US | claimed |
| EP-1874317-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2008-01-09 | — | — | EP | claimed |
| WO-2006113919-A2 | ARYL ALKYL ACID DERIVATIVES FOR AND USE THEREOF | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-10-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215780-A1 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity | FABP4, GPR119, LIPC | DGAT1 34/4885KDM4E 817/4885MEN1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.